跳转至内容
Merck
所有图片(1)

Key Documents

OP16

Sigma-Aldrich

Anti-c-ErbB2/c-Neu (Ab-4) Mouse mAb (7.16.4)

liquid, clone 7.16.4, Calbiochem®

别名:

Anti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
NACRES:
NA.43

生物源

mouse

品質等級

抗體表格

purified antibody

抗體產品種類

primary antibodies

無性繁殖

7.16.4, monoclonal

形狀

liquid

包含

≤0.1% sodium azide as preservative

物種活性

rat, human

製造商/商標名

Calbiochem®

儲存條件

do not freeze

同型

IgG2a

運輸包裝

wet ice

儲存溫度

2-8°C

目標翻譯後修改

unmodified

基因資訊

human ... ERBB2(2064)

一般說明

Anti-c-ErbB2/c-Neu (Ab-4), mouse monoclonal, clone 7.16.4, recognizes ~185 kDa c-ErbB2 in overexpressing B104-1-1 cells. It is validated for WB, IP, ICC, frozen sections, & growth inhibition assay.
Purified mouse monoclonal antibody generated by immunizing C3H mice with the specified immunogen and fusing splenocytes with NS-1 mouse myeloma cells (see application references). Recognizes the ~185 kDa c-ErbB2/c-neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in overexpressing B104-1-1 cells.

免疫原

B104-1-1 cells overexpressing rat c-ErbB2/c-Neu
Epitope: Within the extracellular domain
Human

應用


Frozen Sections (5 g/ml, see application references)
Immunoblotting (see application references)
Immunocytochemistry (5 g/ml)
Immunoprecipitation (1 g/ml, see application references)
Neutralization Studies (not recommended, see application references)

包裝

Please refer to vial label for lot-specific concentration.

警告

Toxicity: Standard Handling (A)

外觀

In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.

分析報告

Negative Control
Fisher rat embryo cells
Positive Control
B104-1-1 cells

其他說明

Stains frozen tissue sections of rat cells overexpressing c-neu. Does not inhibit in vitro protein-tyrosine kinase activity, but it will inhibit in vivo growth of tumors overexpressing the neu oncogene (see application references). Does not cross-react with the EGF receptor. Antibody should be titrated for optimal results in individual systems.
Zhang, H., et al. 1999. Exp. Mol. Pathol.67, 15.
Peterson, N,C., and Greene, M.I., 1988. DNA Cell Biol.17, 1031.
Kokai, Y., et al. 1988. Proc. Natl. Acad. Sci. USA85, 5389.
Van De Vijver, M.J., et al. 1988. New Engl. J. Med.319, 1239.
DiFiore, P.P., et al. 1987. Science237, 178.
Kokai, Y., et al. 1987. Proc. Natl. Acad. Sci. USA84, 8498.
Slamon, D.J., et al. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Michela Lizier et al.
Oncotarget, 7(38), 60793-60806 (2016-08-27)
Cell fusion between neoplastic and normal cells has been suggested to play a role in the acquisition of a malignant phenotype. Several studies have pointed to the macrophage as the normal partner in this fusion, suggesting that the fused cells
Rebecca A Rozich et al.
Experimental and molecular pathology, 89(3), 248-259 (2010-07-27)
Cholangiocarcinoma, a severe form of biliary cancer, has a high mortality rate resulting partially from the advanced stage of disease at earliest diagnosis. A better understanding of the progressive molecular and cellular changes occurring during spontaneous cholangiocarcinogenesis is needed to
Heather Gibson et al.
Oncoimmunology, 4(1), e984523-e984523 (2015-05-08)
The goal is to elucidate the immune modulating activity of an adenovirus (Adv) vector which showed therapeutic activity in human clinical trials. The oncolytic adenovirus (Adv/CD-TK) expressing two suicide genes was tested in two HER2/neu positive BALB/c mouse mammary tumor
Kristina W Thiel et al.
Nucleic acids research, 40(13), 6319-6337 (2012-04-03)
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers.
Jason J Northey et al.
The Journal of biological chemistry, 288(7), 5210-5222 (2013-01-02)
The ErbB2 and TGFβ signaling pathways cooperate to promote the migratory, invasive, and metastatic behavior of breast cancer cells. We previously demonstrated that ShcA is necessary for these synergistic interactions. Through a structure/function approach, we now show that the phosphotyrosine-binding

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门